These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38211479)

  • 41. Increased susceptibility of mice infected with Schistosoma mansoni to recombinant vaccinia virus: association of viral persistence with egg granuloma formation.
    Actor JK; Marshall MA; Eltoum IA; Buller RM; Berzofsky JA; Sher A
    Eur J Immunol; 1994 Dec; 24(12):3050-6. PubMed ID: 7805733
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trypanosoma cruzi: Does the intake of nanoencapsulated benznidazole control acute infections?
    Dutra da Silva A; Fracasso M; Bottari NB; Gundel S; Ourique AF; Assmann CE; Ferreira DASP; Castro MFV; Reichert KP; de Souza LAF; da Veiga ML; da Rocha MIUM; Monteiro SG; Morsch VM; Chitolina Schetinger MR; da Silva AS
    Exp Parasitol; 2023 Jun; 249():108520. PubMed ID: 37001581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of Trypanosoma cruzi infection on nitric oxide synthase and arginase expression and activity in young and elderly mice.
    Felizardo AA; Caldas IS; Mendonça AAS; Gonçalves RV; Tana FL; Almeida LA; Novaes RD
    Free Radic Biol Med; 2018 Dec; 129():227-236. PubMed ID: 30248443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
    Barbosa JMC; Pedra Rezende Y; de Melo TG; de Oliveira G; Cascabulho CM; Pereira ENGDS; Daliry A; Salem KS
    Microbiol Spectr; 2022 Feb; 10(1):e0185221. PubMed ID: 35138142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benznidazole alters the pattern of Cyclophosphamide-induced reactivation in experimental Trypanosoma cruzi-dependent lineage infection.
    Santos DM; Martins TA; Caldas IS; Diniz LF; Machado-Coelho GL; Carneiro CM; Oliveira Rde P; Talvani A; Lana M; Bahia MT
    Acta Trop; 2010 Feb; 113(2):134-8. PubMed ID: 19854145
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved efficacy and safety of low doses of benznidazole-loaded multiparticulate delivery systems in experimental Chagas disease therapy.
    García MC; Eberhardt N; Sanmarco LM; Ponce NE; Jimenez-Kairuz AF; Aoki MP
    Eur J Pharm Sci; 2021 Sep; 164():105912. PubMed ID: 34133985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: a substudy from the BENEFIT trial.
    Moreira OC; Ramírez JD; Velázquez E; Melo MF; Lima-Ferreira C; Guhl F; Sosa-Estani S; Marin-Neto JA; Morillo CA; Britto C
    Acta Trop; 2013 Jan; 125(1):23-31. PubMed ID: 22982466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nasal administration of Schistosoma mansoni egg antigen-cholera B subunit conjugate suppresses hepatic granuloma formation and reduces mortality in S. mansoni-infected mice.
    Sun JB; Stadecker MJ; Mielcarek N; Lakew M; Li BL; Hernandez HJ; Czerkinsky C; Holmgren J
    Scand J Immunol; 2001 Nov; 54(5):440-7. PubMed ID: 11696194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic effects of benznidazole in Swiss mice that are orally inoculated with Trypanosoma cruzi IV strains from the Western Brazilian Amazon.
    Teston APM; Fernandes NS; Abegg CP; de Abreu AP; Sarto MPM; Gomes ML; Toledo MJO
    Exp Parasitol; 2021 Sep; 228():108136. PubMed ID: 34280400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Th1 to Th2 shift induced by Schistosoma mansoni does not exacerbate murine aids (MAIDS).
    Lacroix C; Akarid K; Chau F; Sinet M; Verola O; Carbon C; Derouin F
    Parasite Immunol; 1998 Oct; 20(10):497-501. PubMed ID: 9797511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
    Ferraz ML; Gazzinelli RT; Alves RO; Urbina JA; Romanha AJ
    Antimicrob Agents Chemother; 2009 Jan; 53(1):174-9. PubMed ID: 19001113
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distinct Treatment Outcomes of Antiparasitic Therapy in
    Albareda MC; Natale MA; De Rissio AM; Fernandez M; Serjan A; Alvarez MG; Cooley G; Shen H; Viotti R; Bua J; Castro Eiro MD; Nuñez M; Fichera LE; Lococo B; Scollo K; Tarleton RL; Laucella SA
    Front Immunol; 2018; 9():1958. PubMed ID: 30271399
    [No Abstract]   [Full Text] [Related]  

  • 53. In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole.
    Murta SM; Romanha AJ
    Parasitology; 1998 Feb; 116 ( Pt 2)():165-71. PubMed ID: 9509026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains.
    Veloso VM; Carneiro CM; Toledo MJ; Lana M; Chiari E; Tafuri WL; Bahia MT
    Mem Inst Oswaldo Cruz; 2001 Oct; 96(7):1005-11. PubMed ID: 11685270
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
    Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
    Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models.
    Gulin JEN; Eagleson MA; López-Muñoz RA; Solana ME; Altcheh J; García-Bournissen F
    Acta Trop; 2020 Nov; 211():105606. PubMed ID: 32598923
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro and in vivo antiparasitic activity of Physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi.
    Meira CS; Guimarães ET; Dos Santos JA; Moreira DR; Nogueira RC; Tomassini TC; Ribeiro IM; de Souza CV; Ribeiro Dos Santos R; Soares MB
    Phytomedicine; 2015 Oct; 22(11):969-74. PubMed ID: 26407938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model.
    Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F
    Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The immunomodulatory activity of Chenopodium ambrosioides reduces the parasite burden and hepatic granulomatous inflammation in Schistosoma mansoni-infection.
    Rodrigues JGM; Albuquerque PSV; Nascimento JR; Campos JAV; Godinho ASS; Araújo SJ; Brito JM; Jesus CM; Miranda GS; Rezende MC; Negrão-Corrêa DA; Rocha CQ; Silva LA; Guerra RNM; Nascimento FRF
    J Ethnopharmacol; 2021 Jan; 264():113287. PubMed ID: 32858197
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypansoma cruzi population.
    Murta SM; Ropert C; Alves RO; Gazzinelli RT; Romanha AJ
    Parasite Immunol; 1999 Oct; 21(10):535-44. PubMed ID: 10610497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.